Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Leiomyosarcoma × niraparib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Ovarian Neoplasms 25 Prostatic Neoplasms 8 Fallopian Tube Neoplasms 8 Breast Neoplasms 7 Pancreatic Neoplasms 5 Neoplasm Metastasis 4 Endometrial Neoplasms 4 Neoplasms 3 Mesothelioma 3 Lung Neoplasms 3 Head and Neck Neoplasms 3 Glioblastoma 3 Triple Negative Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Recurrence 2 Mesothelioma, Malignant 2 Melanoma 2 Esophageal Neoplasms 2 Colorectal Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Renal Cell 2 Uveal Melanoma 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urologic Neoplasms 1 Thrombocytopenia 1 Stomach Neoplasms 1 Solid Tumor 1 Sarcoma 1

Interventions

Gemcitabine 12 Doxorubicin 7 Docetaxel 7 Trabectedin 5 pazopanib 4 Temozolomide 3 Specimen Handling 3 Sorafenib 3 Nivolumab 3 brostallicin 2 Sunitinib 2 Radiotherapy 2 Radiation Dose Hypofractionation 2 Magnetic Resonance Spectroscopy 2 Letrozole 2 Dacarbazine 2 Bevacizumab 2 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 2 tremelimumab 1 talimogene laherparepvec 1 sotigalimab 1 soblidotin 1 saracatinib 1 rucaparib 1 rubitecan 1 romidepsin 1 ridaforolimus 1 ribociclib 1 reolysin 1 perifosine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05174455 2023-09-18

Niraparib for the Treatment of Leiomyosarcoma

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn

Leiomyosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡